Two radically new drugs bring hope to people with depression. But psychiatrists are skeptical.

Both drugs have been criticized for their high cost and the fact that both are difficult to implement. Brexanolone costs an average of $ 34,000, plus the cost of a long hospital stay – although FDA approval means that insurance can cover at least part of the fee. In the meantime, in order to gain a profit from ketamine, which cannot be patented, Johnson & Johnson's research firm, Janssen, isolated S-ketamine, one of the two visibility molecules that make up the compound of the original drug, and transformed it into a nasal spray. One dose of the resulting product, acetamin, costs up to $ 885, and this is above the fees for managing the clinic – a requirement because the substance is still "classified".